Significant investment at Kulmbach site expands capacity of specialist therapeutic oligonucleotide development solutions business
Replaces Dr Derek Craston, who completed two terms of five years each in this Office
First phase began in July 2017 and has just been completed
Moves strengthen existing analytical and bioanalytical drug development service offering
Supports qNMR facility in providing reference material characterisation and quantitative measurement research for customers
Making scientific innovation an intrinsic part of delivering a world-class NHS
LGC operates out of 22 countries, with laboratories and centres across Europe and the US, as well as sites in Brazil, China and India.